Effect of ESAT-6 on human T cell Function

ESAT-6 对人 T 细胞功能的影响

基本信息

  • 批准号:
    7860399
  • 负责人:
  • 金额:
    $ 17.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-05 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Tuberculosis remains a major global health problem and vaccine development is a critical priority. T-cells play a pivotal role in protection against Mycobacterium tuberculosis. However, M. tuberculosis is known to inhibit human immunity, but the mechanisms are not well understood. Early secreted antigenic target of 6 kD (ESAT-6) is an immunogenic protein that is a potential vaccine candidate, but also contributes to virulence and cytolysis of mammalian cells. Our preliminary data indicate that ESAT-6 directly inhibits human T cell proliferation and IFN-g secretion, and these effects are not due to cytotoxicity or increased apoptosis. Our goal is to understand the molecular mechanisms by which ESAT-6 inhibits human T cell IFN-g production. The specific aims are: 1. Identify the signaling pathways by which ESAT-6 inhibits T cell IFN-g production. We will determine the effect of ESAT-6 on transcription factors that bind to the IFN-g proximal promoter, using promoter pull-down assays and chromatin immunoprecipitation (aim 1.1). We will evaluate the effect of ESAT-6 on molecules that mediate signaling through the T-cell receptor (aim 1.2) and on the intermediary signaling molecules, mitogen-activated protein kinases (aim 1.3), using immunoprecipitation, Western blotting and functional kinase assays 2. Identify a mammalian ligand for ESAT-6 on human T-cells. We will use biotinylated ESAT-6 to pull down proteins from extracts of purified T-cells, elute the proteins, separate them by SDS-PAGE and identify them by mass spectrometry (aim 2.1). The putative ligand will be cloned and expressed, and interactions between ESAT-6 and its ligand will be confirmed by surface plasmon resonance and protein overlay assays (aim 2.2). To determine the functional significance of the interaction between ESAT-6 and its putative ligand, we will determine if neutralizing antibodies and/or siRNA to the ESAT-6 ligand abrogate the inhibitory effects of ESAT-6 on T-cells (aim 2.3). PUBLIC HEALTH RELEVANCE: Tuberculosis remains a tremendous public health problem world-wide, and an effective vaccine would contribute greatly to disease control. Early secreted antigenic target of 6 kD (ESAT-6) is a Mycobacterium tuberculosis protein that is a promising vaccine candidate, but also contributes to virulence and tissue damage. This proposal seeks to understand the mechanisms by which ESAT-6 inhibits human T-cell immune function, information that is critical for development of improved vaccines and treatment strategies for tuberculosis.
描述(由申请人提供):结核病仍然是一个主要的全球卫生问题,疫苗开发是一个关键的优先事项。t细胞在抵抗结核分枝杆菌方面起着关键作用。然而,已知结核分枝杆菌可抑制人体免疫,但其机制尚不清楚。早期分泌的6kd抗原靶标(ESAT-6)是一种免疫原性蛋白,是一种潜在的候选疫苗,但也有助于哺乳动物细胞的毒力和细胞溶解。我们的初步数据表明,ESAT-6直接抑制人T细胞增殖和IFN-g分泌,这些作用不是由于细胞毒性或细胞凋亡增加。我们的目标是了解ESAT-6抑制人类T细胞IFN-g产生的分子机制。具体目标是:1。确定ESAT-6抑制T细胞IFN-g产生的信号通路。我们将使用启动子下拉试验和染色质免疫沉淀(目的1.1)来确定ESAT-6对结合IFN-g近端启动子的转录因子的影响。我们将评估ESAT-6对通过t细胞受体介导信号传导的分子(aim 1.2)和中间信号传导分子,丝裂原活化蛋白激酶(aim 1.3)的影响,使用免疫沉淀,Western blotting和功能激酶测定2。鉴定ESAT-6在人t细胞上的哺乳动物配体。我们将使用生物素化的ESAT-6从纯化的t细胞提取物中提取蛋白质,洗脱蛋白质,用SDS-PAGE分离它们,并用质谱法鉴定它们(目的2.1)。假设的配体将被克隆和表达,ESAT-6与其配体之间的相互作用将通过表面等离子体共振和蛋白质覆盖测定来确认(目标2.2)。为了确定ESAT-6与其假定的配体之间相互作用的功能意义,我们将确定中和ESAT-6配体的抗体和/或siRNA是否会消除ESAT-6对t细胞的抑制作用(目的2.3)。公共卫生相关性:结核病仍然是世界范围内一个巨大的公共卫生问题,有效的疫苗将大大有助于疾病控制。早期分泌6kd抗原靶点(ESAT-6)是一种结核分枝杆菌蛋白,是一种有希望的候选疫苗,但也有助于毒力和组织损伤。该提案旨在了解ESAT-6抑制人类t细胞免疫功能的机制,这一信息对于开发改进的结核病疫苗和治疗策略至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Buka Samten其他文献

Buka Samten的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Buka Samten', 18)}}的其他基金

Suppression of Allograft Rejection by A Novel Protein ESAT-6
新型蛋白质 ESAT-6 抑制同种异体移植排斥
  • 批准号:
    8427281
  • 财政年份:
    2012
  • 资助金额:
    $ 17.63万
  • 项目类别:
ESAT-6 primes dendritic cells with reduced IL-12 and increased IL-23 production
ESAT-6 启动树突状细胞,减少 IL-12 的产生并增加 IL-23 的产生
  • 批准号:
    8282486
  • 财政年份:
    2012
  • 资助金额:
    $ 17.63万
  • 项目类别:
Suppression of Allograft Rejection by A Novel Protein ESAT-6
新型蛋白质 ESAT-6 抑制同种异体移植排斥
  • 批准号:
    8224077
  • 财政年份:
    2012
  • 资助金额:
    $ 17.63万
  • 项目类别:
ESAT-6 primes dendritic cells with reduced IL-12 and increased IL-23 production
ESAT-6 启动树突状细胞,减少 IL-12 的产生并增加 IL-23 的产生
  • 批准号:
    8448065
  • 财政年份:
    2012
  • 资助金额:
    $ 17.63万
  • 项目类别:
Effect of ESAT-6 on human T cell Function
ESAT-6 对人 T 细胞功能的影响
  • 批准号:
    7640305
  • 财政年份:
    2009
  • 资助金额:
    $ 17.63万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.63万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 17.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了